The Antidiabetic Properties Of Glp In Type Diabetes And Limitations To Its Therapeutic

In patients with type 2 diabetes, the incretin effect is reduced or absent (47). GLP-1 secretion is diminished in type 2 diabetic subjects, possibly contributing to the reduced incretin effect (48). A continuous intravenous GLP-1 infusion stimulates insulin secretion and normalizes both fasting and postprandial blood glucose in patients with type 2 diabetes (29,49). A continuous subcutaneous administration for 6 weeks reduced diurnal glucose concentrations and HbA1c by 1.3% and suppressed glucagon secretion (38). Furthermore, the patients treated with GLP-1 lost approximately 2 kg of weight (Fig. 1)

The multiple actions of GLP-1 constitute a novel and attractive therapeutic principle for the treatment of type 2 diabetes by improving the postprandial metabolic situation and eliminating hypoglycemic events (Table 1) (38). The risk of hypoglycemia observed in patients treated with GLP-1 is minimal because GLP-1 only stimulates insulin secretion under hyperglycemic conditions (33,51). Intravenous infusions of GLP-1 can normalize plasma glucose in patients with type 2 diabetes. Hepatic glucose production is lowered due to the inhibition of glucagon secretion (29) and the effects on body weight are also desirable.

Effects of a single subcutaneous injection of GLP-1, however, were disappointing due to the very rapid degradation of GLP-1 in vivo (52). GLP-1 (and the other incretin, GIP) is degraded within a few minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) (53,54). Due to the enzymatic degradation, only approximately 20% of the GLP-1 administered by an intravenous infusion reaches circulation intact and in a biologically active form (38,54).

Generally, either DPP-4-resistant GLP-1 receptor agonists or substances inhibiting DPP-4 could be used to utilize the therapeutic potential of GLP-1 (55).

Peptidergic GLP-1 receptor agonists (GLP-1 analogs, also termed "incretin mimetics") are currently being introduced into type 2 diabetes therapy as injectable compounds (26,55-58). On the other hand, various orally active DPP-4 inhibitors are also evaluated in clinical trials or approved in single countries (26).


The first "incretin mimetic" available in the United States for the therapy of type 2 diabetic patients not optimally controlled with an oral antidiabetic therapy (sulfonylureas and/or metformin) is exenatide [Byetta®; Eli Lilly (Indianapolis, IN, U.S.A.) & Amylin Pharmaceuticals (San Diego, CA, U.S.A.)]. Exenatide is the synthetic recombinant form of the naturally occurring peptide exendin-4. Exendin-4 was discovered in the salivary gland of the Gila monster (Heloderma suspectum). It has a high amino acid sequence similarity to GLP-1 and is not cleaved by DPP-4. Exendin-4 has physiological effects comparable to GLP-1 and a biological half-life of several hours making a therapy with twice daily injections feasible (59). In clinical studies exenatide showed a significant

FIGURE 1 The entero-insular axis. Postpran-dially, insulin secretion is directly stimulated by substrates and by the strong endocrine stimulation through incretin hormones. Abbreviations: AA, amino acids; CHO, carbohydrates; FA, fatty acids; H+, protons from gastric acid. Source: From Ref. 1.

TABLE 1 Organ-Specific Effects of GLP-1

Organ/cell system

GLP-1 effect

Endocrine pancreas

Beta cells

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook

Post a comment